Stem Cell Therapy: Where Do the Stem Cells Come From
Bone marrow, fat tissue, and umbilical cord: a plain-language guide to where stem cells used in therapy come from and why source and handling matter.

Three tissues, one clinical question
When patients ask about stem cell therapy, the first question is almost always the same: where do the stem cells come from? The answer shapes everything else, from how cells are collected and processed to what the evidence currently supports and what remains under study. Before any conversation about protocols or candidacy, that question deserves a clear, clinical answer.
This article covers the three tissue sources most discussed in regenerative medicine today: bone marrow, adipose (fat) tissue, and umbilical cord tissue. It does not cover embryonic stem cells, which belong to a separate scientific and regulatory category and are not a topic in clinical regenerative medicine as we practice it. The question of whether a person's own cells or a donor's cells are used is a distinct discussion we address separately.
Bone marrow: the source with the longest clinical record
Bone marrow is the tissue inside certain bones where the body continuously produces blood cells. It is one of the original sources identified for stem cell therapy, and its use in hematology, particularly for blood and immune system conditions, is well established in medicine. When clinicians discuss stem cells from bone marrow in a regenerative context, they are referring to a population called mesenchymal stem cells, which are distinct from the blood-forming cells used in transplantation for cancer care.
In general, bone marrow collection for regenerative purposes involves a procedure called aspiration, most commonly from the posterior iliac crest, a flat area at the back of the hip bone. A needle is inserted under local anesthesia and a small volume of marrow is drawn out. The procedure takes place in a clinical setting and requires sterile technique throughout.
Once collected, the aspirate goes through a processing step to isolate and concentrate the cell population of interest. The quality of that processing, including the equipment used, the handling time, and the environment in which it occurs, directly affects what is delivered. Processing standards vary considerably between facilities, and that variation is clinically meaningful. A cell population that has been handled correctly behaves differently from one that has not.
Bone marrow aspiration is accepted medical practice with a defined procedural profile. Its use specifically for musculoskeletal and orthopedic indications in a regenerative context is an area where evidence continues to develop, and not every proposed application carries the same level of support.
The source of the cells is only one variable. How those cells are collected, processed, and handled before they reach the patient is equally part of the clinical decision.
Adipose tissue: a more accessible source under active study
Adipose tissue, the fat layer beneath the skin, contains a population of mesenchymal stem cells that can be isolated and used in regenerative protocols. This source has drawn significant research interest in part because the collection procedure is less invasive than bone marrow aspiration and the tissue is relatively abundant in most adults.
In general, collection involves a small-volume lipoaspiration, typically from the abdomen or flank, performed under local anesthesia. The harvested tissue then undergoes enzymatic or mechanical processing to separate the cellular fraction from fat and connective tissue.
The resulting product is sometimes referred to as the stromal vascular fraction (SVF), a mixed population that includes mesenchymal stem cells alongside other cell types such as endothelial progenitors and immune-modulating cells. Some protocols use this mixed fraction directly; others involve further steps to select or expand specific populations. These are not equivalent approaches, and the distinction matters when evaluating what a protocol actually delivers.
Research into adipose-derived cells is active across several areas, including orthopedics, wound healing, and inflammatory conditions. What the evidence supports at this stage, what is still under investigation, and what does not yet have a clinical basis are questions that require honest, indication-by-indication answers. For a fuller picture of how evidence and limits are framed in this field, our article on what stem cells are used for: evidence and limits covers that ground in detail.
Umbilical cord tissue: donor-sourced cells and what that means
Umbilical cord tissue, specifically the gelatinous connective tissue known as Wharton's jelly, is a rich source of mesenchymal stem cells. Unlike bone marrow or adipose tissue, these cells come from a donor: cord tissue is collected at birth, with informed consent from the mother, and then processed and banked for later therapeutic use. Because collection occurs after delivery, there is no harm to the newborn or the mother.
Cord-tissue mesenchymal stem cells have properties that researchers find relevant to regenerative medicine. They are generally considered immunologically tolerant, meaning the body is less likely to mount a rejection response compared to other donor cell types, though this does not mean reactions are impossible. They also tend to show high replicative activity, which is relevant to both their potential usefulness and to the standards that must govern their banking and quality control.
The clinical and regulatory status of umbilical cord-derived products varies by country. In Mexico, cell therapies operate under the oversight of COFEPRIS, the federal regulatory authority. In the United States and Canada, the FDA and Health Canada respectively govern what is permitted. A facility that handles banked cord tissue must meet defined standards for donor screening, processing, storage, and documentation. When evaluating any provider, asking specifically about regulatory standing and cell bank certification is not a secondary concern: it is a primary one.
What science currently supports for cord-tissue mesenchymal stem cells, and where the evidence base is still forming, follows the same pattern as other regenerative sources. Some applications have more clinical grounding than others, and honest communication about that distinction is part of responsible practice. If you are comparing providers and want a framework for what questions to ask, our article on stem cell therapy in Mexico: how to evaluate a clinic provides exactly that.
A cell bank's documentation is not paperwork. It is the only way to know that what is being administered has been screened, processed, and stored to a verifiable standard.
How cells are harvested: what the collection process involves
Understanding how stem cells are harvested for stem cell therapy matters because collection is not passive. Each source involves a defined procedure, a defined level of clinical risk, and a defined set of standards that must be met for the cells to be viable and safe.
For autologous sources (the patient's own tissue), collection and use typically occur in the same clinical encounter or within a short window. Bone marrow aspiration and adipose lipoaspiration are both outpatient procedures when performed correctly, but they are still medical procedures. They require appropriate anesthesia, sterile technique, trained personnel, and a processing environment that meets clinical standards. The cell population degrades with time and with temperature variation: there is no margin for improvised handling.
For allogeneic sources (donor tissue, such as cord-derived products), the collection has already occurred, but the chain of custody matters just as much. Screening of the donor, processing of the tissue, cryopreservation, storage temperature, and documentation of the entire sequence are all variables that affect what arrives at the point of care. A product without a traceable chain of custody from collection to administration is a product without a verifiable safety profile.
flowchart TD
A["Tissue source identified"] --> B{"Autologous or allogeneic?"}
B -->|"Patient's own tissue"| C["Bone marrow aspiration\nor adipose collection"]
B -->|"Donor tissue"| D["Cord tissue: collected\nat birth, donor-screened"]
C --> E["Processing and\ncell isolation"]
D --> F["Banking, cryopreservation\nand quality control"]
E --> G["Clinical assessment\ndetermines indication"]
F --> G
G --> H["Protocol defined\nand documented in writing"]
H --> I["Administration and\nmedically supervised follow-up"]
Why source and processing determine the clinical picture
Patients sometimes encounter the phrase "stem cell therapy" applied to procedures that differ substantially from one another: the source, the processing method, the cell population delivered, and the regulatory context can all vary. Where stem cell injections come from is therefore not a branding question. It is a clinical one, and it is the right question to ask any provider before agreeing to a protocol.
Processing quality determines whether the cells administered are viable, whether contaminants have been removed, and whether the concentration matches what the protocol requires. A facility that performs the procedure in a non-clinical environment, that does not document processing steps, or that cannot explain the origin and handling of the cells it uses is not offering a different product. It is offering an unverifiable one.
The source also shapes the indication. Bone marrow-derived cells, adipose-derived cells, and cord-tissue-derived cells are not interchangeable. Research in each area has its own profile, its own current limits, and its own open questions. A protocol that does not specify the source, the processing method, and the clinical rationale for that combination has not yet told you what it is actually proposing.
Source, processing, and indication are three separate variables. When one of them is unclear, the clinical picture is incomplete.
What an assessment looks like at Longevia Medical
At Longevia Medical, in Puerto Cancún, care in regenerative medicine begins with a clinical assessment. That assessment can be conducted in person or as a remote assessment before you travel. The purpose is to evaluate your situation with the information available and determine whether a regenerative protocol is indicated and, if so, what form it should take.
The plan that results from the assessment is individual and given to you in writing. It includes the clinical rationale, the protocol structure, and the follow-up framework. Follow-up continues after you return home, because the clinical picture does not end when a session does. Medical supervision applies throughout.
Nothing about the source of cells, the processing involved, or the indication for any protocol is decided before that assessment takes place. Whether something applies to your situation is exactly what the assessment is for.
Frequently Asked Questions
In stem cell therapy, where do the stem cells come from?
The three main sources discussed in clinical regenerative medicine are bone marrow, adipose (fat) tissue, and umbilical cord tissue. Bone marrow and adipose tissue are typically collected from the patient; cord tissue comes from a donor and is banked after birth. Each source involves different collection methods, processing requirements, and evidence profiles.
How are stem cells harvested for stem cell therapy?
Bone marrow is collected by aspiration, typically from the hip bone under local anesthesia. Adipose tissue is collected by small-volume lipoaspiration. Umbilical cord tissue is collected at birth with donor consent and then processed and banked. All methods require sterile conditions, trained personnel, and defined processing standards to preserve cell viability.
Where do stem cell injections come from, and does the source matter?
Yes, the source matters clinically. Bone marrow, adipose, and cord-tissue cells are not interchangeable: each has a different cell population, a different evidence base, and different processing requirements. A protocol that does not specify the source and processing method has not fully disclosed what it is proposing.
Are embryonic stem cells used in these therapies?
Embryonic stem cells belong to a separate scientific and regulatory category. They are not part of the clinical regenerative medicine discussed here. The sources addressed in current practice are adult mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord tissue.
What questions should I ask a provider about cell source and processing?
Ask specifically: what tissue source is used, whether cells are from the patient or a donor, how processing is performed and where, what documentation exists for the chain of custody, and what regulatory framework governs the procedure. A provider who cannot answer these questions clearly is not yet offering complete information.
For patients who want to read further as general background, Mayo Clinic and MedlinePlus both publish patient-oriented information on stem cells and regenerative medicine.
Begin privately
Tell us what you want to protect.
This first conversation is for orientation, not diagnosis. A coordinator will identify the right clinical pathway and explain the secure next step.
Request a private consultation↗